Patients bearing the MRP2 variant Gly40Ala showed a weak association with survival and tumor response to gemcitabine therapy and, surprisingly, this association diminished in patients receiving gemcitabine/cisplatin plus radiotherapy [154]. The gene discussed is ABCC2; the disease is neoplasm.